Short answer
Perspective Therapeutics, Inc. (CATX) filed an 8-K current report with the SEC on September 14, 2026 reporting Item 8.01 (Other Events), Item EX-99.1 (Exhibit EX-99.1). Item 8.01 references Exhibit 99.1, containing a press release likely providing the material event details.
Perspective Therapeutics, Inc. 8-K event analysis
AI summary of each reported item and its exhibits
Item 8.01 · Other Events
- Item 8.01 references Exhibit 99.1, containing a press release likely providing the material event details
- Filing signed by CEO Johan (Thijs) Spoor on September 14, 2026
Item EX-99.1 · Exhibit EX-99.1
- Merck collaboration adds Keytruda to PSV359’s Phase 1/2a trial in FAP-α-positive solid tumors
- Merck supplying pembrolizumab at no cost, limiting combination-study drug expense for Perspective
- Trial amendment targets non-small cell lung and colorectal cancers; first three monotherapy dose cohorts enrolled
- Strategic validation from a major oncology partner, but clinical efficacy and safety remain unproven
- PSV359’s development remains dose-finding, with future expansion dependent on establishing a recommended Phase 2 dose
Generated from the filing text and exhibits; verify against the original. What 8-K item codes mean
Other Perspective Therapeutics, Inc. 8-K filings
Get the next CATX 8-K as it lands
Follow CATX for push alerts, or ask the research agent what this filing means.